Peter Keane

1.6k total citations
32 papers, 1.2k citations indexed

About

Peter Keane is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Hematology. According to data from OpenAlex, Peter Keane has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 10 papers in Cellular and Molecular Neuroscience and 9 papers in Hematology. Recurrent topics in Peter Keane's work include Acute Myeloid Leukemia Research (9 papers), Receptor Mechanisms and Signaling (8 papers) and Genomics and Chromatin Dynamics (6 papers). Peter Keane is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Receptor Mechanisms and Signaling (8 papers) and Genomics and Chromatin Dynamics (6 papers). Peter Keane collaborates with scholars based in United Kingdom, France and Netherlands. Peter Keane's co-authors include Philippe Soubrié, M. Arnone, Jean‐Pierre Maffrand, Constanze Bonifer, Cathal Seoighe, Peter N. Cockerill, Gérard Le Fur, Vincent Santucci, Jeanne Stemmelin and Caroline Cohen and has published in prestigious journals such as Nature Communications, The EMBO Journal and Bioinformatics.

In The Last Decade

Peter Keane

31 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Keane United Kingdom 17 422 417 361 247 195 32 1.2k
Yukio Shimomura Japan 12 288 0.7× 434 1.0× 324 0.9× 119 0.5× 191 1.0× 15 1.2k
Míriam Hernangómez Spain 16 592 1.4× 193 0.5× 306 0.8× 123 0.5× 55 0.3× 18 1.1k
Thierry Groblewski Canada 12 430 1.0× 600 1.4× 647 1.8× 344 1.4× 49 0.3× 17 1.4k
Cathleen Gonzales United States 23 162 0.4× 614 1.5× 715 2.0× 167 0.7× 79 0.4× 29 1.5k
Jonathon M. Willets United Kingdom 24 247 0.6× 811 1.9× 505 1.4× 177 0.7× 86 0.4× 62 1.3k
Yasue Horiuchi Japan 25 333 0.8× 475 1.1× 405 1.1× 147 0.6× 69 0.4× 61 1.5k
Claude Chevillard France 19 74 0.2× 533 1.3× 305 0.8× 205 0.8× 166 0.9× 85 1.2k
Brice Ongali Canada 19 154 0.4× 303 0.7× 228 0.6× 451 1.8× 56 0.3× 39 1.2k
Amador Haro Spain 15 772 1.8× 379 0.9× 458 1.3× 144 0.6× 110 0.6× 37 1.2k
Lakshmi Thirumangalakudi United States 11 57 0.1× 295 0.7× 226 0.6× 461 1.9× 52 0.3× 16 1.2k

Countries citing papers authored by Peter Keane

Since Specialization
Citations

This map shows the geographic impact of Peter Keane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Keane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Keane more than expected).

Fields of papers citing papers by Peter Keane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Keane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Keane. The network helps show where Peter Keane may publish in the future.

Co-authorship network of co-authors of Peter Keane

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Keane. A scholar is included among the top collaborators of Peter Keane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Keane. Peter Keane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coleman, Daniel, Peter Keane, Paulynn Suyin Chin, et al.. (2024). Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. iScience. 27(4). 109576–109576. 7 indexed citations
2.
Potluri, Sandeep, Peter Keane, Helen J. Blair, et al.. (2024). Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nature Communications. 15(1). 1359–1359. 16 indexed citations
3.
Goode, Debbie K., Peter Keane, Salam A. Assi, et al.. (2023). A genome-wide relay of signalling-responsive enhancers drives hematopoietic specification. Nature Communications. 14(1). 267–267. 14 indexed citations
4.
Coleman, Daniel, Peter Keane, Paulynn Suyin Chin, et al.. (2023). Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth. Cell Reports. 42(12). 113568–113568. 6 indexed citations
5.
Keane, Peter, et al.. (2023). Chromatin priming elements direct tissue-specific gene activity before hematopoietic specification. Life Science Alliance. 7(2). e202302363–e202302363. 3 indexed citations
6.
Adamo, Assunta, Paulynn Suyin Chin, Peter Keane, et al.. (2022). Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia. Leukemia. 37(1). 102–112. 9 indexed citations
7.
Keane, Peter, et al.. (2021). Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories. Life Science Alliance. 4(2). e202000864–e202000864. 13 indexed citations
8.
Keane, Peter, et al.. (2020). RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks. Haematologica. 106(6). 1569–1580. 8 indexed citations
9.
Bevington, Sarah L., et al.. (2020). Chromatin Priming Renders T Cell Tolerance-Associated Genes Sensitive to Activation below the Signaling Threshold for Immune Response Genes. Cell Reports. 31(10). 107748–107748. 22 indexed citations
10.
Gilmour, Jane, Christopher Middleton, Peter Keane, et al.. (2019). Robust hematopoietic specification requires the ubiquitous Sp1 and Sp3 transcription factors. Epigenetics & Chromatin. 12(1). 33–33. 23 indexed citations
11.
Boer, Bauke de, Maurien Pruis, Peter Keane, et al.. (2018). Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. Cancer Cell. 34(4). 674–689.e8. 59 indexed citations
12.
Keane, Peter & Cathal Seoighe. (2016). Intron Length Coevolution across Mammalian Genomes. Molecular Biology and Evolution. 33(10). 2682–2691. 19 indexed citations
13.
Stemmelin, Jeanne, Caroline Cohen, İpek Yalçın, Peter Keane, & Guy Griebel. (2009). Implication of β3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. Behavioural Brain Research. 206(2). 310–312. 26 indexed citations
14.
15.
Stemmelin, Jeanne, Caroline Cohen, Jean-Paul Terranova, et al.. (2007). Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders. Neuropsychopharmacology. 33(3). 574–587. 90 indexed citations
16.
Lemaire, Laurent, Jacqueline Fournier, Yann Le Fur, et al.. (2002). Magnetic Resonance Imaging of the Neuroprotective Effect of Xaliproden in Rats. Investigative Radiology. 37(6). 321–327. 7 indexed citations
17.
Alonso, Richard, M. Arnone, Robert Boigegrain, et al.. (1999). SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. II: In Vivo Pharmacological Characterization. Journal of Pharmacology and Experimental Therapeutics. 289(2). 752–761. 25 indexed citations
18.
Vita, Natalio, Florence Oury-Donat, Pascale Chalon, et al.. (1998). Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. European Journal of Pharmacology. 360(2-3). 265–272. 112 indexed citations
19.
Poncelet, Martine, M. Arnone, Michel Héaulme, et al.. (1993). Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist. Naunyn-Schmiedeberg s Archives of Pharmacology. 348(1). 102–107. 23 indexed citations
20.
Santucci, Vincent, et al.. (1985). EEG effects of IV infusion of pentylenetetrazol in rats: A model for screening and classifying antiepileptic compounds. Psychopharmacology. 87(3). 337–343. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yukio Shimomura Breakdown of academic impact, for papers by Míriam Hernangómez Breakdown of academic impact, for papers by Thierry Groblewski Breakdown of academic impact, for papers by Cathleen Gonzales Breakdown of academic impact, for papers by Jonathon M. Willets Breakdown of academic impact, for papers by Yasue Horiuchi Breakdown of academic impact, for papers by Claude Chevillard Breakdown of academic impact, for papers by Brice Ongali Breakdown of academic impact, for papers by Amador Haro Breakdown of academic impact, for papers by Lakshmi Thirumangalakudi
Rankless by CCL
2026